• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

eFoodSafety.Com, Inc. Subsidiary, Knock-Out Technologies, Ltd. To Conduct Human Clinical Trials Based on Documented Independent Laboratory Results; Human Clinical Studies to Commence

Posted on: Tuesday, 17 January 2006, 12:00 CST

Robert Bowker, President/CEO of Knock-Out Technologies, Ltd., a wholly owned subsidiary of eFoodSafety.com, Inc. (OTCBB:EFSF) announced today that Bucks County Clinical Research, Inc. (BCCR) agreed to conduct human clinical trials on Knock-Out Technologies' newly formulated ingestible products after a thorough review of our independent laboratory results and material safety data sheets. This research allows eFoodSafety the ability to document and substantiate our impact on Healthcare in Human subjects.

Bucks County Clinical Research, Inc. (http://bccrinc.com/) is a clinical research facility in its 28th year of performing Human Clinical Studies. This is a fully-licensed FDA approved facility that has successfully completed over 270 clinical trials, and is currently performing 7 clinical trials with major pharmaceutical companies. Some of the major pharmaceutical companies that have conducted their trials with BCCR include GlaxoSmithKline (NYSE: GSK), Pfizer (NYSE: PFE), and Eli-Lilly (NYSE: LLY). Please go to http://bccrinc.com/ for a more complete list. With a population base of over one million to draw from, and a group of 47 physicians and consultants practicing 23 subspecialties, patient visits last year exceeded 150,000. BCCR is well suited to conduct our human clinical trials. Richard M. Goldfarb M.D., FACS, a Director of eFoodSafety.com, Inc. and President of MedElite, Inc., a wholly-owned subsidiary of eFoodSafety.com, Inc., serves as Medical Director of Research & Development at Bucks County Clinical Research, Inc.

Patricia Ross-Gruden, President/CEO of eFoodSafety,com, Inc. stated, "With such an outstanding reputation and experience in performing clinical trials for major pharmaceutical companies, we feel fortunate that our cutting edge products will be studied under the same stringent criteria to which the major pharmaceutical companies must adhere."

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and most recently became a distributor for Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements invoke risk and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

Source: Business Wire

More News in this Category